Explore the Agenda

9:00 am Registration & Networking

Morning Workshop

10:00 am Spotlight on In Vivo Development in Asia to Inform Global Clinical Development Strategies

Chief Scientific Officer, Stylus Medicine
Founder & Chief Scientific Officer, Alaya.bio

As in vivo cell and gene therapies moves into the clinic worldwide, diverse regulatory  pathways across Asia are shaping how quickly first patients are dosed. This workshop examines the role of Asia with a focus on China’s investigator-initiated trials and what  global sponsors can responsibly learn from them. 

This workshop will:

  • Cover essential elements of study design, CMC planning, safety monitoring, ethics, and data quality
  • Explain how to effectively bridge investigator-initiated trials into registrational pathways
  • Provide clear decision criteria and practical guidance on when to leverage Asian clinical evidence
  • Share collaboration models and a practical playbook for integrating Asian data into global development plans

12:30 pm Lunch Break

Afternoon Workshop

1:30 pm Enabling Extrahepatic Delivery to Increase the Range of Treatable Diseases

Founder & Chief Executive Officer, Cytodigm

As in vivo therapies expand beyond the liver, enabling extrahepatic delivery is essential  to unlock new indications. This workshop explores strategies to reach CNS, bone  marrow, lung, kidney and immune cells using approaches highlighted across the field.

This workshop will:

  • Compare extrahepatic delivery strategies including localized routes, passive targeting, antibody- or bispecific mediated attachment, and next-generation LNP/viral designs
  • Outline how teams evaluate biodistribution, species differences and regulatory expectations for non-hepatic targeting
  • Provide a framework to select and validate delivery approaches that broaden the treatable disease landscape
  • Share practical considerations to reduce CMC burden while achieving precise extrahepatic tropism

4:00 pm End of Workshop Day